SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced data from the Phase II study with its Captisol-enabled®, propylene glycol-free (PG-free) melphalan.
This Phase II study compared the safety, tolerability and pharmacokinetic profiles of a new PG-free melphalan intravenous formulation and the current clinically used intravenous formulation of melphalan (sold as Alkeran®) for multiple myeloma patients undergoing autologous transplantation. This Captisol-enabled product is expected to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.
